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Potential novel pharmacological therapies for myocardial
remodelling
Abstract
Left ventricular (LV) remodelling remains an important treatment target in patients after myocardial
infarction (MI) and chronic heart failure (CHF). Accumulating evidence has supported the concept that
beneficial effects of current pharmacological treatment strategies to improve the prognosis in these
patients, such as angiotensin-converting enzyme (ACE) inhibition, angiotensin type 1 receptor blocker
therapy, and beta-blocker therapy, are related, at least in part, to their effects on LV remodelling and
dysfunction. However, despite modern reperfusion therapy after MI and optimized treatment of patients
with CHF, LV remodelling is observed in a substantial proportion of patients and is associated with an
adverse clinical outcome. These observations call for novel therapeutic strategies to prevent or even
reverse cardiac remodelling. Recent insights from experimental studies have provided new targets for
interventions to prevent or reverse LV remodelling, i.e. reduced endothelial nitric oxide (NO)
synthase-derived NO availability, activation of cardiac and leukocyte-dependent oxidant stress
pathways, inflammatory pathway activation, matrix-metalloproteinase activation, or stem cell transfer
and delivery of novel paracrine factors. An important challenge in translating these observations from
preclinical studies into clinical treatment strategies relates to the fact that clinical studies are designed on
top of established pharmacological therapy, whereas most experimental studies have tested novel
interventions without concomitant drug regimens such as ACE inhibitors or beta-blockers. Therefore,
animal studies may overestimate the effect of potential novel treatment strategies on LV remodelling
and dysfunction, since established pharmacological therapies may act, in part, via identical or similar
signalling pathways. Nevertheless, preclinical studies provide essential information for identifying
potential novel targets, and their potential drawbacks, and are required for developing novel clinical
treatment strategies to prevent or reverse LV remodelling and dysfunction.
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ABSTRACT 
Left ventricular (LV) remodeling remains an important treatment target in patients 
after myocardial infarction (MI) and chronic heart failure (CHF). Accumulating 
evidence has supported the concept that beneficial effects of current pharmacological 
treatment strategies to improve the prognosis in these patients, such as angiotensin-
converting enzyme (ACE) inhibition, angiotensin type 1 (AT1) receptor blocker 
therapy, and β-blocker therapy, are related, at least in part, to their effects on LV 
remodeling and dysfunction. However, despite modern reperfusion therapy after MI 
and optimized treatment of patients with CHF, LV remodeling is observed in a 
substantial proportion of patients and is associated with adverse clinical outcome. 
These observations call for novel therapeutic strategies to prevent or even reverse 
cardiac remodeling. 
 Recent insights from experimental studies have provided new targets for 
interventions to prevent or reverse LV remodeling, i.e. reduced endothelial nitric 
oxide (NO) synthase-derived NO availability, activation of cardiac and leukocyte-
dependent oxidant stress pathways, inflammatory pathway activation, matrix-
metalloproteinase (MMP) activation, or stem cell transfer and delivery of novel 
paracrine factors. An important challenge in translating these observations from 
preclinical studies into clinical treatment strategies represents the fact that clinical 
studies are designed on top of established pharmacological therapy, whereas most 
experimental studies have tested novel interventions without concomitant drug 
regimens such as ACE-inhibitors or β-blockers. Therefore, animal studies may 
overestimate the effect of potential novel treatment strategies on LV remodeling and 
dysfunction, since established pharmacological therapies may act, in part, via 
identical or similar signaling pathways. Nevertheless, pre-clinical studies provide 
essential information for identifying potential novel targets, and their potential 
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drawbacks, and are required for developing novel clinical treatment strategies to 
prevent or reverse LV remodeling and dysfunction. 
 
 
INTRODUCTION 
Left ventricular maladaptive remodeling has been consistently associated with an 
impaired prognosis in patients after MI and patients with CHF [1-3], and is thought to 
represent an important therapeutic target in these patients. Mechanical reperfusion 
therapy and current pharmacological treatment approaches can limit, to some extent, 
cardiac dysfunction and adverse LV remodeling in patients with an acute MI, 
however, LV remodeling is still observed in a substantial proportion of these patients 
despite modern reperfusion therapy, and is most prominent in patients with large 
anterior infarctions and/or microvascular dysfunction [4-6]. Recent insights into 
molecular mechanisms leading to LV remodeling and dysfunction, such as 
inflammatory pathway activation, oxidant stress pathway activation, and matrix 
metalloproteinase activation, provide potential novel targets for prevention or reversal 
of LV remodeling and dysfunction. 
Whereas in clinical studies, LV remodeling has largely been assessed by 
analyzing changes in LV end-diastolic and end-systolic volumes, experimental 
studies have mostly analyzed the effects of novel interventions on cardiomyocyte 
hypertrophy, myocardial fibrosis, re-expression of an embryonic gene expression 
pattern, and LV dilation and dysfunction. Importantly, LV remodeling may not only 
lead to a progressive LV dilation and dysfunction, but may also be associated with 
the risk of ventricular arrhythmias [7]. Therefore, an altered LV architecture and 
function during post-infarction LV remodeling are likely important substrates for 
triggering malignant ventricular arrhythmias. 
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Left ventricular remodeling is thought to represent a valuable surrogate 
endpoint for novel therapeutic interventions in patients with MI or CHF. In support of 
this concept, beneficial effects on LV remodeling by both, pharmacological and non-
pharmacological therapies have been associated with beneficial effects on prognosis 
in these patients. This has been observed for ACE-inhibitor and β-blocker therapy as 
described below. Furthermore, recently it was demonstrated in patients with CHF 
receiving cardiac resynchronization therapy, that LV reverse remodeling but not 
clinical improvement predicted long-term survival [8], further supporting the concept 
that adverse LV remodeling represents an important therapeutic target. However, as 
a note of caution, like with most surrogate endpoints in clinical studies, not all 
therapies that were associated with a beneficial effect on LV remodeling were later 
associated with improved clinical outcome, suggesting that disease progression may 
also occur in other ways and in the absence of progressive cardiac remodeling. For 
example, treatment with the soluble TNF-α antagonist etanercept improved LV 
remodeling and dysfunction in a study of patients with severe CHF [9], but was later 
not associated with an improvement in clinical outcome in larger studies [10]. The 
underlying reasons for these different observations are not completely understood, 
but likely include potential adverse effects of TNF-α antagonism and potential 
beneficial effects of cytokine activation in patients with CHF [11]. In fact, most, but 
not, all interventions that attenuated LV remodeling had a benefical effect on survival 
in clinical trials. Thus, remodeling appears to represent an attractive surrogate 
endpoint in treatment trials but does not, of course, replace outcome trials. However, 
prevention of LV remodelling, per se, is an important target for therapeutic 
interventions. Specifically, interventions that attenuate LV remodeling but do not 
improve outcome are likely to adversely affect mortality for other and contrasting 
effects on a cellular or molecular level; e.g. surgical partial left ventriculectomy or 
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surgical inhibition of LV volume expansion by implantation of a CorCap device do not 
provide beneficial effects probably because surgery is associated with detrimental 
architectural effects and/or impaired relaxation which may counteract the beneficial 
effects of the primary surgical target. Thus, while targeting LV remodelling should 
represent an attractive surrogate and target, the limitations are obvious and therefore 
targeting LV remodelling does no replace clinical outcome trials but rather represents 
a useful tool in the development of a new therapeutic intervention.  
 
In this review we briefly summarize the effects of current pharmacological 
therapies on LV remodeling and dysfunction. We then focus on potential novel 
pharmacological approaches to prevent or reverse LV remodeling and dysfunction 
based on recent insights into the molecular mechanisms leading to LV remodeling 
and dysfunction (Table).  
 
 
CURRENT PHARMACOLOGICAL APPROACHES TO LIMIT CARDIAC REMODELING 
ACE-inhibitors / AT1-receptor blockers 
ACE-inhibitors attenuate LV remodeling in patients after MI with reduced LVEF [12], 
and this has been suggested to contribute to their beneficial effects on prognosis. 
This concept has been strongly supported by the observation that attenuation of 
ventricular enlargement with the ACE-inhibitor captopril was associated with a 
reduction in adverse events in patients after MI, suggesting a link between 
attenuation of LV enlargement by captopril and improved clinical outcome [13]. The 
VALIANT (Valsartan in Acute Myocardial Infarction Trial) echo substudy examined 
the effect of combined ACE-inhibitor / AT1-receptor blocker therapy on LV remodeling 
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in patients after MI with reduced systolic function and/or with CHF. A more complete 
inhibition of the renin-angiotensin aldosterone system (RAAS) by combining ACE-
inhibitor and AT1-receptor blocker therapy did not promote additional effects on 
cardiac volumes or LVEF and clinical outcome as compared to either therapy alone 
in these patients [14].  
By contrast, a subgroup analysis from Val-HeFT (Valsartan Heart Failure Trial) 
has shown that in patients with CHF and a reduced LVEF combination of the 
AT1-receptor blocker valsartan with ACE-inhibitor therapy had a more pronounced 
effect on LV remodeling as compared to ACE-inhibitor therapy alone [15]. In these 
patients, LVEF increased, and LV end-diastolic dimension decreased significantly 
more with combined and prolonged RAAS blockade [15]. Furthermore, results from 
the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and 
Morbidity) trial program are in support of a prognostic benefit of adding the 
AT1-receptor antagonist candesartan to ACE-inhibitor and ß-blocker therapy in 
patients with CHF and a reduced LVEF [16]. 
 
Beta-blockers 
Prolonged therapy with several β-blockers has been suggested to limit and, in a 
substantial proportion of patients, even to reverse LV remodeling and dysfunction 
after MI or in CHF. The CAPRICORN (Carvedilol Post Infarction Survival Control in 
Left Ventricular Dysfunction) echo substudy has demonstrated a beneficial effect of 
the β-blocker carvedilol on LV remodeling in patients with post MI LV dysfunction 
receiving ACE-inhibitor therapy; carvedilol reduced LV end-systolic volume and 
improved LVEF as compared to placebo in that study [17].  
In patients with CHF, treatment with metoprolol exerted a beneficial effect on LV 
remodeling already after 3 months of therapy [18]. In the magnetic resonance 
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imaging (MRI) substudy of MERIT-HF (Metoprolol Randomized Intervention Trial in 
Heart Failure), reverse LV remodeling was observed after metoprolol succinate 
therapy [19]. Similarly, carvedilol therapy reduced LV volumes and increased LVEF in 
patients with CHF due to ischemic heart disease on-top-of ACE-inhibitor therapy [20], 
and these changes have been suggested to explain, at least in part, improved clinical 
outcomes. Moreover, Metra et al. have reported that patients with CHF who showed 
a marked improvement in LVEF after 9 to 12 months of β-blocker therapy with 
metoprolol or carvedilol had an excellent prognosis, further suggesting that beneficial 
effects of β-blockers on LV remodeling and dysfunction are associated with improved 
clinical outcomes [21]. Preservation of LV function has also been observed after 5 
months of bisoprolol therapy in patients with CHF and this treatment effect was 
related to an improved prognosis [22]. In elderly patients with CHF and advanced LV 
systolic dysfunction, nebivolol therapy reduced LV size and improved LVEF as 
reported in the echocardiographic substudy of the SENIORS (Study of the Effects of 
Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart 
Failure) trial [23]. Taken together, there is clear evidence for these four β-blockers to 
exert beneficial effects on LV remodeling and dysfunction, and that these changes 
are related to beneficial effects on prognosis in patients with CHF. 
As it is a current focus to better identify and treat patients with asymptomatic 
LV dysfunction in order to prevent the development of CHF, the results of the recent 
REVERT (Reversal of Ventricular Remodeling with Toprol-XL) study are of interest. 
These investigators have shown that metoprolol succinate therapy reverses LV 
remodeling and dysfunction in patients with asymptomatic LV systolic dysfunction 
[24]. 
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Aldosterone-antagonists 
Aldosterone, which is also produced by endothelial and vascular smooth-muscle cells 
in the heart, may exert potent detrimental effects on LV remodeling, including a 
stimulation of myocardial fibrosis [25, 26]. In line with this concept, Chan et al. have 
recently observed in an MRI study that adding spironolactone to AT1-receptor blocker 
therapy with candesartan reduces LV end-diastolic and end-systolic volumes in 
patients with mild-to-moderate CHF over a 1-year follow-up [27]. The observed 
reductions in LV volumes and mass and the improvement of LVEF suggest that 
spironolactone may exert beneficial myocardial structural effects.  
 
 
NOVEL PHARMACOLOGICAL APPROACHES  
Statins 
While 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, also known as 
statins, have a well-established role in the treatment and prevention of ischemic 
coronary artery disease, their usefulness in the setting of CHF and LV dysfunction 
remains under investigation. In addition to a reduction in LDL, statins clearly have the 
potential to exert additional, “pleiotropic” cardiac and vascular effects. Several 
experimental studies have shown that statins inhibit cardiomyocyte hypertrophy [28, 
29] and prevent LV remodeling and dysfunction in rodent models of MI [30-32] as 
well as in dogs with microembolization-induced CHF [33]. 
One of the best characterized pleiotropic actions of statin therapy is the effect 
on endothelial NO synthase (eNOS) activity, that likely plays an important role in 
limiting LV remodeling [34]. In mice after MI we have observed that statin therapy 
reduces cardiomyocyte hypertrophy and interstitial fibrosis and improves LV function 
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to a substantially greater extent in wild-type mice as compared to eNOS-deficient 
mice, strongly suggesting that the effect of statins on eNOS plays an important role 
for statin-mediated beneficial effects on LV remodeling [35]. 
An important difference between these preclinical studies and clinical trials is 
that patients in clinical trials are already treated, in the case of patients with CHF with 
ACE-inhibitors, β-blockers, and other drugs, and that the novel substance is then 
tested on-top-of a complex drug regime. However, in a small, randomized clinical 
study by Node et al. including 51 patients with CHF and non-ischemic dilated 
cardiomyopathy, short-term (14 weeks) simvastatin therapy modestly improved LV 
function as examined by echocardiography and clinical status [36]. Moreover, we 
have observed a beneficial effect of statin therapy on endothelial NO availability in 
patients with CHF due to non-ischemic cardiomyopathy, that was independent of LDL 
lowering, because it was not seen with the same degree of LDL reduction after 
ezetimibe therapy, suggesting that statin therapy augments eNOS activity in patients 
with CHF independent of its effects on LDL cholesterol [37]. Furthermore, in an 
echocardiographic study by Sola et al. that included 108 patients with non-ischemic 
CHF and a LVEF ≤35%, the use of atorvastatin improved LVEF by approximately 4% 
and reduced LV end-diastolic diameter by about 4 mm as compared to placebo [38]. 
Krum et al. have conducted a 6-month randomized placebo-controlled study of high-
dose rosuvastatin in 86 patients with ischemic or non-ischemic CHF and a 
LVEF<40% and did not observe a significant change in LVEF as detected by 
radionuclide ventriculography or LV end-diastolic diameter as measured by 
echocardiograhy [39]. The reasons for these discrepant findings remain uncertain, 
but may be related to differences in the patient populations and statin doses. 
In retrospective analyses, statin therapy has been associated with an 
improved survival in ischemic and non-ischemic cardiomyopathy [40] and a reduced 
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development of CHF in patients with stable coronary disease [41]. Furthermore, high-
dose as compared to moderate-dose statin therapy was associated with reduced 
CHF hospitalizations in patients with pre-existing CHF and an acute coronary 
syndrome or in patients with stable coronary disease [42, 43]. In the CORONA 
(Controlled Rosuvastatin Multinational Trial in Heart Failure) trial that examined an 
elderly patient population (mean age, 73 years) with ischemic systolic CHF, 
rosuvastin therapy did not significantly reduce the primary end-point of death from 
cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, or reduce 
the number of deaths from any cause, although the drug did reduce the number of 
cardiovascular hospitalizations [44]. Notably, CORONA was designed to test the 
hypothesis that a reduction of ischemia in ischemic cardiomyopathy by LDL lowering 
and preventing the progression of coronary artery disease results in improved 
outcomes. The relatively low dose of rosuvastatin that was used in CORONA may 
not exert much of the pleiotropic effects required for myocardial effects with impact 
on LV remodeling. However, the GISSI-HF (GISSI Heart Failure) trial has examined 
the role of statin therapy in a population with ischemic and non-ischemic 
cardiomyopathy [45], and the results are completely neutral. 
The above observations may support the notion that statins exert beneficial 
effects in earlier stages of heart failure and may attenuate the development of heart 
failure. By contrast, the benefits of statin therapy are likely limited in elderly patients 
with advanced CHF and established ischemic cardiomyopathy.  
 
Nitric oxide-cGMP signaling as a therapeutic target 
The free radical gas NO, which is produced in the heart by virtually all cell types and 
by all three NOS isoforms, is an important modulator of cardiomyocyte function and 
survival besides its well known impact on the vascular system. NO at low 
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concentrations protects cardiomyocytes from ischemia/reperfusion-injury via soluble 
guanylyl cyclase activation and cGMP formation [47-51]. Moreover, NO has been 
shown to exert beneficial effects on LV remodeling post MI [46]. Potential 
downstream targets for NO/cGMP-mediated effects in cardiomyocytes include 
cGMP-regulated phosphodiesterases and cGMP-dependent protein kinase type 1 
(PKG I) (Figure 1). Previous studies have implicated PKG I in the regulation of the 
inotropic state, hypertrophic growth, and gene expression in cardiomyocytes after 
exposure to NO and other cGMP-elevating agents [52-56]. Recently we found that 
PKG I protects cardiomyocytes from apoptotic cell death during ischemia/reperfusion-
injury, in part, via inhibition of TAB1-p38 signaling [57]. Takimoto et al. have recently 
shown that inhibition of cGMP phospodiesterase 5A may provide an attractive 
pharmacological means to take advantage of the beneficial effects of cGMP. By 
inhibiting the breakdown of cGMP, a sustained activation of PKG I can occur thus 
preventing and reversing cardiac hypertrophy and remodeling [58]. Additional 
approaches to stimulate NO or its signaling pathways may be the use of β-blockers 
with NO enhancing properties [59] or NO-enhancing drugs [60]. 
Importantly, however, the source and amount of nitric oxide likely play a critical role 
for the effects of NO on cardiac remodeling and dysfunction. Whereas low doses of 
NO produced by endothelial NO synthase have consistently been observed to exert 
cardioprotective effects in numerous preclinical studies, large amounts of NO as 
produced by inducible NO synthase have been suggested to exert detrimental effects 
and are not necessarily cardioprotective [61-63]. This may, at least in part, be 
explained by increased peroxynitrite formation, as is observed in cardiomyocyte 
iNOS overepressing mice [64]. 
 
Potential targets for selective anti-oxidant therapy 
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Over the last years numerous experimental studies have demonstrated a critical role 
of oxidant stress pathways for LV remodeling and dysfunction after MI. We have 
observed that mice which are deficient in the NAD(P)H oxidase subunit p47phox 
show a marked reduction in cardiomyocyte hypertrophy, LV dilation and dysfunction 
after MI [65] (Figure 2). Reduced MMP-2 activation and cardiomyocyte apoptosis in 
the infarct border zone likely contribute to the protection from LV remodeling in these 
mice. Moreover, in this study we have observed that cardiac xanthine oxidase 
activation after MI was dependent on NAD(P)H oxidase activation. Xanthine oxidase 
has been proposed to be involved in LV remodeling and dysfunction in several 
experimental and small-scale clinical studies [66, 67].  
In a small clinical study, Cingolani et al. have observed that 1 month of therapy 
with the xanthine oxidase inhibitor oxipurinol improves LVEF in patients with CHF 
and a LVEF <40% [68]. In the OPT-CHF (Oxypurinol Therapy for CHF) study, Hare 
et al. have examined the effects of oxipurinol in 402 patients with advanced systolic 
CHF receiving optimal medical therapy [69]. While oxipurinol did not produce clinical 
improvements in unselected CHF patients, a post-hoc analysis suggested that 
benefits may occur in patients with elevated serum uric acid and in relation to the 
degree of uric acid reduction. Accordingly, serum uric acid may serve as a potential 
biomarker to target xanthine oxidase inhibition in CHF [69], however, this will have to 
be tested in a prospective study. 
Furthermore, experimental studies using myeloperoxidase (MPO)-deficient 
mice have suggested that leukocyte-derived, MPO-generated oxidants have a 
profound adverse effect on LV remodeling and function after MI [70, 71]. Cardiac 
MPO activation may also be targeted by anti-inflammatory treatment strategies as 
described below. 
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Taken together, the present studies suggest that production of oxidant radicals 
by NAD(P)H oxidase, xanthine oxidase, or myeloperoxidase is critically involved in 
LV dilation and dysfunction after MI and in CHF. However, the ideal target to interfere 
with myocardial oxidant stress is still to be identified. 
 
Anti-inflammatory treatment strategies 
Several studies have shown that inflammation contributes importantly to 
LV remodeling processes. The major challenge for an effective anti-inflammatory 
strategy to prevent or reverse LV remodeling is to limit detrimental inflammatory cell-
mediated changes, while simultaneously maintaining adequate and appropriate 
LV repair responses. The initial remodeling phase after MI leading to a removal of 
necrotic debris and to scar formation (infarct healing) should probably be considered 
beneficial as it serves to maintain LV structural integrity and to prevent LV rupture. 
Interference with the process of scar formation during the acute post MI period, e.g. 
by administration of glucocorticosteroids and nonsteroidal anti-inflammatory drugs 
(NSAID), has been suggested to result in increased thinning of the infarct zone and 
potentially greater degrees of infarct expansion. Therapy with NSAIDs (ibuprofen and 
indomethacin) in the early post MI period resulted in an increased thinning of the 
infarct zone in experimental studies [72, 73]. More recently, Timmers et al have 
reported that therapy with the COX-2 inhibitor celecoxib increased mortality and 
enhanced LV remodeling and dysfunction in a pig model after MI [74]. 
By contrast, studies in rodent models, such as in rats after MI [75], have 
reported beneficial effects of COX-2 inhibition on LV dysfunction when therapy was 
started late after MI. In a recent study in a rodent model, Fang et al. examined 
inflammatory cell infiltration, MMP-9 activation and the risk of cardiac rupture after MI 
[76]. Inflammatory cell infiltration was greater in male as compared to female mice 
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and was associated with a higher risk of cardiac rupture, potentially due to increased 
MMP-9 activation [76]. Moreover, several recent experimental studies have 
suggested that specific anti-inflammatory interventions may exert potent beneficial 
effects on LV remodeling and dysfunction, raising the possibility that an appropriately 
timed and targeted anti-inflammatory therapeutic intervention may exert beneficial 
effects on LV remodeling and dysfunction.  
Innate immunity-toll-like receptors: Toll-like receptors (TLRs), primary innate 
immune receptors that are also activated by endogenous signals, such as oxidative 
stress and heat shock proteins, are expressed by cardiomyocytes and vascular cells. 
Of note, LV dilation and dysfunction, mortality, and myocardial fibrosis in the non-
infarcted area were markedly attenuated in TLR-2 deficient mice after MI [77]. 
Furthermore, two recent experimental studies have observed that TLR-4 activation, 
that is increased in the failing myocardium, is an important mediator of maladaptive 
LV remodeling and dysfunction and reduced survival after MI [78, 79]. These studies 
suggest a causal role of TLR-2 and -4 activation in post-MI maladaptive LV 
remodeling, likely mediated via stimulation of pro-inflammatory cytokine production 
and matrix degradation. TLRs may therefore constitute a novel treatment target to 
prevent LV remodeling and dysfunction. Complete inhibition of these pathways may 
yield undesired effects due to functional loss of this innate immune mechanism, 
however, partial inhibition for a limited time period may be beneficial and should be 
further explored. 
Interleukin-1 receptor antagonists: A recent experimental study has shown that 
exogenous administration of a recombinant human IL-1 receptor antagonist 
(anakinra) can reduce cardiomyocyte apoptosis and LV remodeling after acute MI 
[80]. Ikonomidis et al. have reported antioxidant effects and improved LV function 
after short-term anakinra therapy in 23 patients with rheumatoid arthritis [81]. A more 
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detailed understanding of the role of specific inflammatory pathways for LV 
remodeling may provide interesting novel opportunities for therapeutic interventions 
to prevent or reduce LV remodeling. In this context, several factors have recently 
been identified, either by microarray approaches or elucidation of paracrine factors 
released from stem cells, that are involved in the modulation of inflammation and 
cardiac repair mechanisms post MI. Growth-differentiation factor-15, for example, is 
produced in the infarcted and failing heart and has been shown to identify patients at 
high risk for adverse cardiovascular events [82-85]. Moreover, frizzled-related protein 
2 has been shown to markedly attenuate the remodeling process after MI [86]. 
 
Selective matrix metalloproteinase inhibition 
MMPs are a family of proteolytic enzymes promoting extracellular protein degradation 
in the cardiovascular system. They have been shown in several experimental studies 
to participate in the complex remodeling processes of the myocardium after MI and in 
CHF [87]. The biological activity of MMPs is regulated at different levels, i.e. gene 
expression, activation of precursor proenzyme forms, and inhibition by endogenous 
tissue inhibitors of MMPs, the TIMPs. Notably, plasma TIMP-1 (tissue inhibitor of 
metalloproteinase-1) and MMP-9 have been identified as indicators of LV remodeling 
and prognosis in patients after acute MI [88]. 
Selective MMP inhibition has been shown to reduce LV remodeling without 
inhibiting angiogenesis after MI in experimental models [89]. In the PREMIER 
(Prevention of Myocardial Infarction Early Remodeling) trial [90], the first human 
therapeutic study with an MMP inhibitor in patients after MI, 253 patients with first 
ST-segment elevation MI (LVEF <40%) were randomized to placebo or the oral MMP 
inhibitor PG-116800, that previously exerted significant anti-remodeling effects in 
animal models of MI and ischemic CHF [91]. However, after 90 days of follow-up no 
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significant effects on LV remodeling or clinical outcome were noted in that study [90]. 
PG-116800 is a MMP inhibitor of the hydroxamic acid class with high affinity for 
MMP-2, -3, -8, -9, -13, and -14 and low affinity for MMP-1 and -7 [90]. Notably, an 
experimental study by Spinale et al. has demonstrated that MMP inhibition conferred 
a beneficial effect on survival early post MI, but that prolonged MMP inhibition was 
associated with higher mortality rates and adverse LV remodeling, suggesting that 
there may exist an optimal time window with respect to pharmacological interruption 
of MMP activity in the post MI period [92]. In support of this concept, Kelly et al. have 
observed a biphasic profile of plasma MMP-9 that is related to LV remodeling and 
function in patients after MI [93]. Higher early levels of MMP-9 were associated with 
the extent of LV remodeling. In contrast, higher plateau levels late after MI were 
associated with a relative preservation of LV function. Therefore, the temporal profile, 
rather than the absolute magnitude, of MMP-9 activity appears to be important for LV 
remodeling after AMI [93], and likely is important for potential novel therapeutic 
strategies.  
 
Angiogenesis and/or stem cell transfer 
Coronary angiogenesis is enhanced during the acute phase of adaptive cardiac 
growth but is reduced as hearts undergo maladaptive remodeling [94-96]. Coronary 
angiogenesis is associated with the induction of myocardial VEGF and angiopoietin-2 
expression while inhibition of angiogenesis leads to a decreased capillary density, 
contractile dysfunction, and impaired cardiac growth. Endothelium- and 
cardiomyocyte-derived factors are involved in cardiac angiogenesis [95]. Thus, both 
cardiac size and function are angiogenesis dependent, and disruption of coordinated 
tissue growth and angiogenesis in the heart may contribute to the progression from 
adaptive cardiac hypertrophy to CHF. 
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Recent observations indicate that stem and progenitor cells can release pro-
angiogenic factors which in turn, stimulate angiogenesis in the border zone post MI. 
Increased myocardial angiogenesis after stem and progenitor cell transfer has been 
postulated to improve infarct healing and energy metabolism in the infarct border 
zone [97-100]. Early clinical trials suggest that intracoronary delivery of bone marrow 
cells may improve LVEF recovery in patients after MI [101]. More work is needed, 
however, to identify the most suitable cell types and application methods and to 
define the impact of cell therapy on clinical endpoints and other indices of LV 
remodeling, i.e. LV end-diastolic volumes. Furthermore, other delivery strategies for 
pro-angiogenic factors after MI and in CHF need to be explored.  
 
 
CONCLUSIONS 
Left ventricular remodeling remains an important treatment target in patients after MI 
or with CHF. While the beneficial effects of ACE-inhibition, AT1-receptor blocker 
therapy, and β-blocker therapy on LV remodeling are established, adverse LV 
remodeling is still observed in a substantial proportion of patients and is related to an 
adverse prognosis. These observations call for novel therapeutic strategies. Based 
on recent insights into the mechanisms leading to LV remodeling, novel therapeutic 
targets have been proposed, e.g., eNOS-derived NO availability, activation of cardiac 
and leukocyte-dependent oxidant stress pathways, and activation of inflammatory 
pathways and matrix metalloproteinases. It is hoped that these experimental 
observations will eventually be translated into new and successful treatment 
strategies in the clinical arena. 
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FIGURE LEGENDS 
Figure 1. Nitric oxide-cGMP signaling as a potential therapeutic target. cGMP is 
thought to promote anti-hypertrophic / anti-remodeling effects in the heart, at least in 
part via cGMP-dependent protein kinase type I (PKG I) and inhibition of the 
calcineurin-NFAT signaling pathway. cGMP is produced via nitric oxide (NO)-
stimulated soluble guanylyl cyclase (sGC) activation or natriuretic peptide-stimulation 
of the NPRA receptor. cGMP is degraded by phosphodiesterase 5A. sGC activators, 
endothelial NO synthase (eNOS) enhancers and PDE5A inhibitors (e.g. sildenafil) 
may be used to enhance cGMP signaling (see text for further details).  
 
Figure 2. NAD(P)H oxidase as a potential therapeutic target: Effect of NAD(P)H 
oxidase subunit p47phox deficiency on LV remodeling and dysfunction post-
myocardial infarction (modified from [65]): (A) LV end-diastolic diameter of sham-
operated and MI-operated wild-type (WT) and p47phox-/- mice. (B) LV ejection fraction 
of sham-operated and MI-operated WT mice and p47phox-/- mice. (C) Representative 
M-mode echocardiograms obtained from sham-operated and MI-operated mice. 
(D) Myocardial xanthine oxidase activation after MI is dependent on NAD(P)H 
oxidase as determined by ESR spectroscopy measurements of xanthine oxidase 
activity post-MI. ** P<0.01 vs. sham WT, $$ P<0.01 vs. sham p47phox-/-. 
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Table 
Potential Novel Therapeutic Strategies to Prevent or Reverse LV Remodeling 
Modulators of NO activity and signaling pathways 
  Statins 
  Phosphodiesterase 5A inhibitors (e.g., sildenafil) 
  NO enhancer 
  Cyclic guanylyl cyclase activator 
Anti-oxidant strategies (e.g., statins, allopurinol, SOD mimetics) 
Modulators of inflammation and pro-inflammatory cytokines 
Metalloproteinase inhibitors 
Pro-angiogenetic factors and/or cell transfer 
Ryanodine receptor-stabilizing drugs 
Modulators of MEF2 or HDACs 
Antagomirs (micro RNAs controlling growth promoting factors) 
 
List of potential therapeutic strategies to prevent or reverse LV remodeling, some of which are 
discussed in the text. HDAC denotes histone deacetylase; LV, left ventricular; NO, nitric oxide; MEF2, 
myocyte enhancer factor 2; SOD, superoxide dismutase. 
 
